Filana Therapeutics, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 22 →Insiders2 insiders bought $640,749 in 3 open-market buys. No sales.→HoldersVanguard 4.1%Two Sigma Investments 3.5%Marshall Wace, LLP 3.3%→Financing →PeersClosest companies: VTGN, SER, ANTX→
From the filings
Figures
- Net income
- −$42.3Mlast 12 months
- Operating cash flow
- −$29.8Mlast 12 months
- Cash and equivalents
- $82.7Mat the last balance sheet
- Shares outstanding
- 48.3M shareson issue